{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-012079","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.341121+00:00","generated_at":"2026-05-20T18:53:58.604817+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MAIA Biotechnology stockholders approve increase in authorized common shares to 150M","bullets":["Stockholders re-elected Class III directors Jean-Manassé Theagène and Stan V. Smith for three-year terms.","Ratified Grant Thornton LLP as independent auditor for FY2025.","Approved amendment to increase authorized common stock from 70M to 150M shares.","Certificate of Amendment filed on May 22, 2025, effecting the share increase."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-012079","json":"https://secwatch.observer/filing/0001641172-25-012079.json","markdown":"https://secwatch.observer/filing/0001641172-25-012079.md","text":"https://secwatch.observer/filing/0001641172-25-012079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225012079/0001641172-25-012079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225012079/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T18:53:58.604817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}